产品
编 号：F622423
分子式：C28H27N7O2S
分子量：525.62
分子式：C28H27N7O2S
分子量：525.62
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
结构图
CAS No: 1639357-93-9
产品详情
生物活性：
MTR-106 is a potent and orally active G-quadruplex stabilizer and RNA polymerase I inhibitor. MTR-106 induces apoptosis and inhibits cell growth. MTR-106 can be used in research of cancer.
体内研究：
MTR-106 (10-30 mg/kg; 口服; 每周两次, 持续 29 天) 抑制裸鼠中 BRCA 缺陷和 PARPi 抗性异种移植物的肿瘤生长。Animal Model:BRCA-deficient and PARPi-resistant xenografts in nude mice
Dosage:10, 20, and 30 mg/kg
Administration:oral administration; twice a week, for 29 days
Result:Inhibited tumor growth in a dose-dependent manner.
体外研究：
MTR-106 (0-100 μM; 7 d) 在 HR 缺陷细胞和 PARPi 耐药细胞中均具有抗肿瘤活性。MTR-106 (0-100 μM; 7 d) 诱导细胞凋亡、细胞周期停滞和 DNA 损伤。
MTR-106 is a potent and orally active G-quadruplex stabilizer and RNA polymerase I inhibitor. MTR-106 induces apoptosis and inhibits cell growth. MTR-106 can be used in research of cancer.
体内研究：
MTR-106 (10-30 mg/kg; 口服; 每周两次, 持续 29 天) 抑制裸鼠中 BRCA 缺陷和 PARPi 抗性异种移植物的肿瘤生长。Animal Model:BRCA-deficient and PARPi-resistant xenografts in nude mice
Dosage:10, 20, and 30 mg/kg
Administration:oral administration; twice a week, for 29 days
Result:Inhibited tumor growth in a dose-dependent manner.
体外研究：
MTR-106 (0-100 μM; 7 d) 在 HR 缺陷细胞和 PARPi 耐药细胞中均具有抗肿瘤活性。MTR-106 (0-100 μM; 7 d) 诱导细胞凋亡、细胞周期停滞和 DNA 损伤。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备